2021
Cross-platform transcriptomic profiling of the response to recombinant human erythropoietin
Wang G, Kitaoka T, Crawford A, Mao Q, Hesketh A, Guppy FM, Ash GI, Liu J, Gerstein MB, Pitsiladis YP. Cross-platform transcriptomic profiling of the response to recombinant human erythropoietin. Scientific Reports 2021, 11: 21705. PMID: 34737331, PMCID: PMC8568984, DOI: 10.1038/s41598-021-00608-9.Peer-Reviewed Original ResearchConceptsRNA-seqDifferential gene expressionPathway enrichment analysisRNA biologyTranscriptomic profilingTarget genesEnrichment analysisGene expressionEPO biologyMicroarray platformGene correlateCross-platform comparisonGenesBiologyImmune regulationHuman erythropoietinTissue protectionProfilingRegulationErythropoietinRecombinant human erythropoietinExpressionImportant toolErythropoiesisOxygen transport
2001
Utilization of technologies to reduce allogeneic blood transfusion in the United States
Hutchinson A, Fergusson D, Graham I, Laupacis A, Herrin J, Hillyer C. Utilization of technologies to reduce allogeneic blood transfusion in the United States. Transfusion Medicine 2001, 11: 79-85. PMID: 11299024, DOI: 10.1046/j.1365-3148.2001.00290.x.Peer-Reviewed Original ResearchConceptsPreoperative autologous donationAcute normovolemic haemodilutionAllogeneic blood transfusionOpen heart surgeryCell salvageEpsilon-aminocaproic acidBlood transfusionTranexamic acidUS hospitalsPeri-operative settingCross-sectional mail surveyRecombinant human erythropoietinHospital bed sizeCent of hospitalsNormovolemic haemodilutionAllogeneic bloodAutologous donationBlood supplyCommon reasonHuman erythropoietinHospitalLack of familiarityTransfusionSurgeryInfrequent use
1997
796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support
Crawford J, Blackwell S, Shoemaker D, Pupa M, Mulhausen T, Herndon J, Winer E, Flynn J, Dempsey H. 796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support. Lung Cancer 1997, 18: 205. DOI: 10.1016/s0169-5002(97)80173-0.Peer-Reviewed Original Research
1993
Erythropoietin Therapy for Anemia of Prematurity
Gallagher P, Ehrenkranz R. Erythropoietin Therapy for Anemia of Prematurity. Clinics In Perinatology 1993, 20: 169-191. PMID: 8458164, DOI: 10.1016/s0095-5108(18)30418-4.Peer-Reviewed Original ResearchConceptsAnemia of prematurityRecombinant human erythropoietin administrationBiology of erythropoietinTreatment of anemiaRecombinant human erythropoietinErythropoietin therapyErythropoietin administrationClinical trialsNeonatal erythropoiesisPrematurityHuman erythropoietinValuable adjunctAnemiaTherapyErythropoietinTreatmentPathophysiologyAdjunctAdministrationTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply